Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387026377> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4387026377 endingPage "AB178" @default.
- W4387026377 startingPage "AB178" @default.
- W4387026377 abstract "Background: Atopic dermatitis (AD) is characterized by intense itch and symptoms that adversely impact quality of life (QoL). Upadacitinib is a selective Janus kinase-1 inhibitor approved for moderate-to-severe AD. We assessed the effect of once daily oral upadacitinib (15 or 30 mg) on patient-reported outcomes for adults and adolescents during the double-blind, placebo-controlled periods of Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD Up (NCT03568318). Assessments included itch (Worst Pruritus Numerical Rating Scale); skin pain and symptom severity (AD Symptom Scale); symptom frequency (Patient Oriented Eczema Measure); and sleep, daily activities, and emotional state (AD Impact Scale). Post-hoc analysis of 2240 adults and 344 adolescents randomized patients was performed. By week 2, more patients receiving upadacitinib achieved a clinically relevant response in itch, skin pain, symptom severity, symptom frequency, sleep, daily activities, and emotional state vs placebo across studies among adults (upadacitinib 15 mg: 30.8-87.3%; upadacitinib 30 mg: 38.0-89.9%; placebo: 2.1- 43.1%; nominal P<.001 for all comparisons) and adolescents (upadacitinib 15 mg: 19.4-82.9%; upadacitinib 30 mg: 35.3-97.6%; placebo: 0-41.0%; nominal P<.05 for 37/42 comparisons). These trends continued through week 16 where response rates for all outcomes improved with upadacitinib vs placebo in adults (upadacitinib 15 mg: 42.9-80.4%; upadacitinib 30 mg: 60.9-84.6%; placebo: 10.1- 38.1%; nominal P<.001 for all comparisons) and adolescents (upadacitinib 15 mg: 33.3-78.0%; upadacitinib 30 mg: 50.0-85.7%; placebo: 2.8-43.6%; nominal P<.05 for 41/42 comparisons). These findings highlight the rapid, sustained efficacy of once daily oral upadacitinib in improving symptom burden and QoL in adults and adolescents with moderate-to-severe AD." @default.
- W4387026377 created "2023-09-26" @default.
- W4387026377 creator A5005987239 @default.
- W4387026377 creator A5014100389 @default.
- W4387026377 creator A5020593835 @default.
- W4387026377 creator A5048424331 @default.
- W4387026377 creator A5070956358 @default.
- W4387026377 creator A5071907436 @default.
- W4387026377 creator A5074767554 @default.
- W4387026377 creator A5077872633 @default.
- W4387026377 creator A5081439498 @default.
- W4387026377 creator A5090452229 @default.
- W4387026377 date "2023-09-01" @default.
- W4387026377 modified "2023-10-16" @default.
- W4387026377 title "42065 Improvement in Itch, Symptoms, and Quality of Life With Upadacitinib Through Week 16 in Adults and Adolescents With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)" @default.
- W4387026377 doi "https://doi.org/10.1016/j.jaad.2023.07.714" @default.
- W4387026377 hasPublicationYear "2023" @default.
- W4387026377 type Work @default.
- W4387026377 citedByCount "0" @default.
- W4387026377 crossrefType "journal-article" @default.
- W4387026377 hasAuthorship W4387026377A5005987239 @default.
- W4387026377 hasAuthorship W4387026377A5014100389 @default.
- W4387026377 hasAuthorship W4387026377A5020593835 @default.
- W4387026377 hasAuthorship W4387026377A5048424331 @default.
- W4387026377 hasAuthorship W4387026377A5070956358 @default.
- W4387026377 hasAuthorship W4387026377A5071907436 @default.
- W4387026377 hasAuthorship W4387026377A5074767554 @default.
- W4387026377 hasAuthorship W4387026377A5077872633 @default.
- W4387026377 hasAuthorship W4387026377A5081439498 @default.
- W4387026377 hasAuthorship W4387026377A5090452229 @default.
- W4387026377 hasConcept C126322002 @default.
- W4387026377 hasConcept C142724271 @default.
- W4387026377 hasConcept C159110408 @default.
- W4387026377 hasConcept C16005928 @default.
- W4387026377 hasConcept C204787440 @default.
- W4387026377 hasConcept C27081682 @default.
- W4387026377 hasConcept C2778329239 @default.
- W4387026377 hasConcept C2779951463 @default.
- W4387026377 hasConcept C42219234 @default.
- W4387026377 hasConcept C67761136 @default.
- W4387026377 hasConcept C71924100 @default.
- W4387026377 hasConceptScore W4387026377C126322002 @default.
- W4387026377 hasConceptScore W4387026377C142724271 @default.
- W4387026377 hasConceptScore W4387026377C159110408 @default.
- W4387026377 hasConceptScore W4387026377C16005928 @default.
- W4387026377 hasConceptScore W4387026377C204787440 @default.
- W4387026377 hasConceptScore W4387026377C27081682 @default.
- W4387026377 hasConceptScore W4387026377C2778329239 @default.
- W4387026377 hasConceptScore W4387026377C2779951463 @default.
- W4387026377 hasConceptScore W4387026377C42219234 @default.
- W4387026377 hasConceptScore W4387026377C67761136 @default.
- W4387026377 hasConceptScore W4387026377C71924100 @default.
- W4387026377 hasIssue "3" @default.
- W4387026377 hasLocation W43870263771 @default.
- W4387026377 hasOpenAccess W4387026377 @default.
- W4387026377 hasPrimaryLocation W43870263771 @default.
- W4387026377 hasRelatedWork W2011012045 @default.
- W4387026377 hasRelatedWork W2019841936 @default.
- W4387026377 hasRelatedWork W2054301101 @default.
- W4387026377 hasRelatedWork W2187963007 @default.
- W4387026377 hasRelatedWork W2313670580 @default.
- W4387026377 hasRelatedWork W3158186989 @default.
- W4387026377 hasRelatedWork W4233016836 @default.
- W4387026377 hasRelatedWork W4376611740 @default.
- W4387026377 hasRelatedWork W4386591841 @default.
- W4387026377 hasRelatedWork W2413468027 @default.
- W4387026377 hasVolume "89" @default.
- W4387026377 isParatext "false" @default.
- W4387026377 isRetracted "false" @default.
- W4387026377 workType "article" @default.